MGX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Metagenomi Therapeutics Inc | Needs refresh | Last updated: 2026-03-29T08:34:16Z

TickerMGX

Market Cap49.7M

Cash RunwayRunway > 12 months

Next CatalystPresentation

Public Research Snapshot

Metagenomi Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for MGX-001 (Preclinical).

Pipeline

Asset	Indication	Modality	Stage	Public Note
MGX-001	n/a	n/a	Preclinical	Public pipeline row
Comprehensive Preclinical Specificity Profiling of MGX-001	Efficient And Targeted Human Genome Editing	n/a	n/a	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Presentation	March 2026	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

catalyst_type | Presentation
catalyst_type | Presentation
catalyst_type | Presentation
catalyst_type | Presentation
catalyst_type | Presentation

Want the full MGX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.